13th June 2018

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

We are enclosing herewith press statement dated 12th June 2018 given by Company's Ugandan subsidiary i.e. Cipla Quality Chemical Industries Limited.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Kamlesh Kulkarni

CiplaQCi
ACCESS TO QUALITY AFFORDABLE MEDICINES

Cipla Quality Chemical Industries Ltd (CiplaQCIL)

Press statement

12th June 2018

Building capacity to mitigate the burden of cancer in Uganda

Over the years, CiplaQCI has made tremendous strides in the fight against HIV/AIDS and malaria through increasing access to vital medicines for the treatment of the two ailments. In the last 10 years 150 million doses of anti-malarials have been supplied to both public and private facilities and 10 million packs of ARVs for HIV patients distributed to 9 countries, including; Uganda, Kenya, Tanzania, Angola, Namibia, Malawi, Pakistan, Cameroon, Commoros Island, South Sudan and Zambia. Now that these great strides have been made, there is need to consolidate these gains through scaling up efforts and funding in order to achieve the UNAIDS 90-90-90 target by 2020 of having 90% of persons living with HIV knowing their HIV status, receiving sustained ARV treatment and achieving viral suppression.

As efforts to consolidate the fight against HIV/AIDS continue in order to curb its spread, Uganda as a country and Africa as a continent are now faced with another bigger hurdle that has caused great t devastation in the recent years! Cancer cases have begun to go on the rise with an estimated 800,000 cases in Uganda alone. The biggest burden is that only 4% of those with cancer are able to access care either due to lack of awareness of their status, inability to access treatment centres and or limited access to treatment. Evidence further suggests that cancer survival rates in Uganda are as low as 13% except for breast cancer which stands at 46%. This is a significant disparity with the developed world where survival rates peak at 95%. Close to 40% of the cancer cases are infection related cancers such as cancer of the cervix, cancer of the liver, cancer of the head and neck, lymphomas among others. The remaining are attributable to various factors including lifestyle choices.

Despite these alarming figures, 30% of all cancers are curable, 30% can be treated by palliation to improve survival and quality of life and 30% prevented through lifestyle changes and immunization.

CiplaQCIL believes that the great disparities in cancer survival rates between Uganda and the developed countries can be bridged through heightened multipronged efforts including, developing local solutions to this local problem through public private partnerships.

Cipla Ltd, the majority shareholder in CiplaQCIL has been a major player in cancer treatment pioneering a number of various generic drugs for cancer in India and other parts of the world. Building on the gains made in increasing access to HIV/AIDS and malaria treatments and faced with the growing burden of cancer in Uganda and Africa, CiplaQCIL, a local manufacturer of lifesaving drugs is once again intent on partnering with the government of Uganda to increase access to cancer treatments and give a ray of hope to thousands of cancer sufferers in the country.

And as part of its growth strategy, CiplaQCIL is evaluating an initial Public offering and Renaissance Capital (Kenya) Limited has been appointed as the official book runner. In the event that this is achieved, a section of the public will have a stake in the Company and will become part of the force providing a solution to diseases that afflict the nation and Africa generally. The transaction would be subject to approval from the relevant market regulators.